Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques

“

TL;DR

This narrative review summarizes the management of benign prostatic obstruction (BPO), covering conservative, medical, and surgical options including TURP, laser therapies, and minimally invasive techniques. The main finding is that treatment selection depends on prostate size, patient preferences, and goals, with newer options like HoLEP and MIST offering advantages in recovery and sexual function preservation. Clinically, the review supports a personalized algorithm integrating shared decision-making and highlights the growing role of minimally invasive therapies.

Full summary

4,081 CHARS

**Background:** Benign prostatic obstruction (BPO) is a common cause of lower urinary tract symptoms (LUTS) in aging men, with a lifetime prevalence of 26.2% and an estimated annual cost burden of $73.8 billion globally. The condition significantly impacts quality of life, comparable to heart attack or stroke. Management has evolved from traditional transurethral resection of the prostate (TURP) to include medical therapies and a wide array of minimally invasive surgical treatments (MIST). This narrative review aims to provide an overview of current techniques to support clinical decision-making.

**Methods:** The paper is a narrative review summarizing existing literature on BPO management. It does not describe a systematic search strategy or inclusion criteria but draws on guidelines from the European Association of Urologists (EAU) and American Urology Association (AUA), as well as key randomized controlled trials (RCTs), meta-analyses, and registry studies. The review covers diagnostic workup, conservative management, medical treatments (alpha blockers, 5-alpha-reductase inhibitors, PDE5 inhibitors, antimuscarinics, beta-3 agonists, combination therapy, and supplements), and surgical options (TURP, open simple prostatectomy, minimally invasive simple prostatectomy, laser therapies, aquablation, Rezūm, prostate artery embolization, prostatic urethral lift, and future modalities like iTind and Optilume).

**Key Results:** The review reports numerous specific findings: - Alpha blockers improve IPSS by 30–45% vs. 10–30% with placebo, but increase fall risk by 14% and fracture risk by 16% within 90 days. Ejaculatory dysfunction odds ratios are 5.88 overall, 8.58 for tamsulosin, and 32.5 for silodosin. - 5-alpha-reductase inhibitors reduce prostate size by ~20% and PSA by 50% over 6–12 months, with sustained flow rates for 6 years (finasteride) and 4 years (dutasteride). - Tadalafil 5 mg improves IPSS and IIEF scores but not Qmax; discontinuation due to adverse events is 79% higher vs. placebo. - Combination therapy (5ARI + alpha blocker) reduces clinical progression risk at 4 years vs. monotherapy. - TURP improves IPSS, Qmax, QoL, and PVR; reoperation rate is 8.3% at 8 years; perioperative mortality is 0.1% at 30 days; overall morbidity is 11.1% (urinary retention 5.8%, UTI 3.6%, transfusion 2.9%, TUR syndrome 1.4%). - HoLEP shows similar efficacy to TURP with fewer complications, shorter catheterization, and shorter hospital stay; long-term follow-up (median 126 months) shows Qmax 16 mL/s, PVR 10 mL, IPSS 5, redo surgery 4.7%, incontinence 5.7%. - Greenlight PVP is non-inferior to TURP in the Goliath RCT; reoperation rate at 12 years is 23.5% vs. 17.8% for TURP. - Aquablation: IPSS improvement at 3 years is 14.4 points vs. 13.9 for TURP; retreatment rate 4.3% vs. 1.5%; anejaculation 10% vs. 36%. - Rezūm: IPSS improvement sustained to 5 years; surgical retreatment rate 4.4–7.5% at 5 years; de novo erectile dysfunction 0–3.1%. - PUL: IPSS improvement 36%, Qmax 50%, QoL 44% at 5 years vs. sham; annual reintervention rate 6%. - iTind: 12-month IPSS reduction 9.25 points, Qmax increase 3.52 mL/s, QoL improvement 1.9 points vs. sham. - Optilume: 49% IPSS improvement at 1 year; serious adverse events in 5 patients (hematuria, false passage).

**Clinical Implications:** The review emphasizes that BPO management should be individualized based on prostate size, patient preferences, comorbidities, and treatment goals. For moderate-to-severe LUTS with prostate volume 30–80 mL, TURP remains a standard option, but newer techniques like HoLEP are preferred for larger prostates (>80 mL) due to lower morbidity. MIST options (PUL, Rezūm, aquablation, iTind, Optilume) offer advantages in preserving sexual function and enabling day-case or local anesthetic procedures, though long-term durability data are still emerging. Cost-effectiveness varies by country and treatment duration. The review supports a shared decision-making approach and highlights the need for multidisciplinary discussions, especially for procedures like PAE.